Date | Price Target | Rating | Analyst |
---|---|---|---|
5/13/2022 | $8.75 | Neutral → Buy | Alliance Global Partners |
1/26/2022 | $28.00 → $25.00 | Buy | Aegis Capital |
8/19/2021 | $35.00 → $28.00 | Buy | Aegis Capital |
Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increaseCore B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring,
Company to host conference call and webcast at 8:30am ET NEW YORK, July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, August 8th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal.ink/3V5ogDP Part
First quarter revenue of $5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues.Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of 176% year over year and 210% sequentially from $1.12 million in the fourth quarter 2023 as the core business continues to gain traction, as well as the addition of Twill Inc. revenues post February 15th closingLaunched the Aetna platform generating revenue in Q1 2024 as Aetna continues to add employers to the pla
The integration of Twill's condition-specific, expert-led peer groups will enhance the member experience and deepen engagement with Dario's proven cardiometabolic solution NEW YORK, Sept. 12, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the integration of condition-specific communities and peer groups with personalized navigation capabilities into its cardiometabolic solution to improve outcomes-based engagement, marking a significant milestone in the integration of the Dario-Twill product offering. Social support plays a key role in chronic condition management by improving the psychological we
New Research Confirms the Benefit of Dario's Integrated, Data-Driven Approach to Health and Chronic Condition Management NEW YORK, Sept. 10, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology. The study demonstrates the effectiveness of Dario's cardiometabolic solution for members living with diabetes or prediabetes and depression. Approximately 18%–25% of people living with type 2 diabetes (T2D) experience depression1. The co-occurrence of these conditions can lead to poor health outcomes and increased costs for
Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increaseCore B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring,
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets
8-K - DarioHealth Corp. (0001533998) (Filer)
10-Q - DarioHealth Corp. (0001533998) (Filer)
S-8 - DarioHealth Corp. (0001533998) (Filer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $28.00 from $35.00 previously
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi
Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand NEW YORK, April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms. Dario also
Mr. Kaplan brings a wealth of experience in business strategy specifically in healthcare and digital health NEW YORK, Feb. 23, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the appointment of Jon Kaplan to serve as a board member effective immediately. Mr. Kaplan is a Managing Director and Senior Partner at Boston Consulting Group (BCG), serving as a core member of the strategy and health care practices and leading BCG's transformation initiative for the future evolution of healthcare in the United States and its impact globally. He has previously served in advisory board roles at digital health